Finance

Drug Stocks In News: Teva Pharmaceutical Industries (NYSE:TEVA), Allergan (NYSE:AGN), Dynavax Technologies Corporation (NASDAQ:DVAX), ISIS Pharmaceuticals (NASDAQ:ISIS)

Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) announces the launch of the generic equivalent to Lunesta(R) (Eszopiclone Tablets, CIV), 1, 2 and 3 mg, in the United States. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.68% in last session and finished the day at $49.61. Traded volume was 2,806.00million shares in the last session and the average volume of the stock remained 7.21million shares. The beta of the stock remained 0.59.

RPS has entered into a U.S. co-promotional partnership with Allergan, Inc. (NYSE:AGN), a global leader in eye care, to increase awareness of dry eye disease related to elevated MMP-9 in tears. Allergan, Inc. (NYSE:AGN) rose 3.09 percent to $127.80 Tuesday on volume of 5.86million shares. The intra-day range of the stock was $123.97 to $127.96. Allergan, Inc. (NYSE:AGN) has a market capitalization of $38.23billion.

Dynavax Technologies Corp. (NASDAQ:DVAX) was the recipient of a significant growth in short interest in the month of January. As of March 31st, there was short interest totalling 30,405,093 shares, a growth of 17.0% from the March 14th total of 25,976,848 shares. Dynavax Technologies Corporation (NASDAQ:DVAX)’s stock on Apr 15, 2014 reported a decrease of -3.33% to the closing price of $1.45. Its fifty two weeks range is $0.98 -$2.68. The total market capitalization recorded $381.14million. The overall volume in the last trading session was 4.84million shares. In its share capital, DVAX has 262.88million outstanding shares.

ISIS Pharmaceuticals Inc (NASDAQ:ISIS) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $35.00 price target on the stock. Zacks’ analyst wrote, “Isis’ net loss of $0.21 per share was wider than the Zacks Consensus Estimate of a loss of $0.17. On Tuesday, shares of ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) dropped -0.57% to close the day at $32.99. Company return on investment (ROI) is -7.50% and its monthly performance is recorded as -29.61%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) quarterly revenue growth is -32.27%.